ProShare Advisors
CKPT

ProShare Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

ProShare Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,383
Closed -$43K – 2378
2021
Q1 		$43K Buy
1,383
+239
+21% +$8.01K ﹤0.01% 2232
2020
Q4 		$30K Buy
+1,144
New +$28.9K ﹤0.01% 2075

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

ProShare Advisors's CKPT Position: Q2 2021 in Review

ProShare Advisors sold out of Checkpoint Therapeutics (CKPT) in Q2 2021, closing a stake of 1,383 shares — an estimated $43K sold.

ProShare Advisors first reported a position in CKPT in Q4 2020 and held it in 2 quarters. The position peaked at $43K in Q1 2021. 69 funds tracked by Wall St. Rank hold CKPT as of Q2 2021.

  • ProShare Advisors reported no remaining Checkpoint Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ProShare Advisors sold 1,383 Checkpoint Therapeutics shares in Q2 2021, an estimated $43K.
  • ProShare Advisors first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 2 quarters.
  • ProShare Advisors's Checkpoint Therapeutics position peaked at $43K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.